A Finnish registry study examined the risk of rehospitalization or death in almost 9000 patients with the first episode of schizophrenia over an observation period of 20 years.
The Institute for Quality and Efficiency in Health Care (IQWiG) on July 16, 2018, published its opinion on cariprazine as part of its „benefit assessment“. It concludes that there is an “indication” that cariprazine has a “non-quantifiable added benefit” in the group of patients with schizophrenia with predominant negative symptoms.
Recordati launched the new antipsychotic cariprazine in Germany in Mid-April. The benefit assessment by the G-BA has therefore started.
A new publication in the prestigious Lancet Psychiatry seems to provide new evidence for the benefits of long-term antipsychotic maintenance treatment in schizophrenia (Hui et al., Lancet Psychiatry 2018). On closer inspection, however, the paper confuses more than it provides new insights.